ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
Completed
- Conditions
- Bladder Function
- Interventions
- Procedure: cystometryProcedure: polysomnography
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01029015
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01028950
A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01023945
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 6
- Registration Number
- NCT01023386
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
Phase 4
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT01018914
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
Phase 3
Completed
- Conditions
- Renal DialysisRenal InsufficiencyChronic Kidney Disease
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 35
- Registration Number
- NCT01017276
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Phase 1
Terminated
- Conditions
- CarcinomaOvarian CancerOvarian DiseasesOvarian Neoplasms
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 4
- Registration Number
- NCT01016054
Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Bioavailability of Solifenacin SuccinatePharmacokinetics of Solifenacin SuccinateHealthy Volunteers
- Interventions
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01015040
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Phase 3
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 893
- Registration Number
- NCT01011205
- Locations
- 🇫🇮
026, Helsinki, Finland
🇧🇾146, Minsk, Belarus
🇧🇪006, Gent, Belgium
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT01009775
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath